GnRHa appeared to be effective in reducing the incidence of treatment-related POF (10.7% vs. 25.3%; RR 0.44, 95% CI, 0.31–0.61; p < 0.00001) and in preserving ovulation, whose incidence was 61.7% vs. 25% in the GnRH-a group and in controls, respectively (RR 2.47, 95% CI, 1.43–4.26; p = 0.001). The gene discussed is GNRH1; the disease is premature menopause.